Amneal Pharmaceuticals, Inc.

“The more time I spend here, the more confused I become.” That was the verdict of Sandoz CEO Richard Saynor on the various frustrations of the US off-patent market, as he explored dysfunctional elemen

Previously facing the prospect of a jury trial beginning next month, Jazz Pharmaceuticals has agreed in principle to pay $145m to resolve certain allegations that its US patent-litigation settlement a

After another loss in the US Court of Appeals, Teva will seek a certiorari review by the US Supreme Court of its long-running inhaler patent case against Amneal . Teva had requested a full panel re

Amneal says the planned portfolio of its glucagon-like peptide-1 (GLP-1) agonist collaboration partner Metsera is “moving swiftly through the drug development phase,” as the US-based firm noted that t